文献速递肾移植

高免疫风险肾移植受者早期方案活检诊断抗体介导排斥反应

Antibody-mediated rejection diagnosed in early protocol biopsies in high immunological risk kidney transplant recipients.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究纳入155例高致敏肾移植受者,其中122例在移植后2周内接受方案活检。13例(10.6%)诊断为极早期抗体介导排斥反应(veABMR),占随访期间所有ABMR的52%。veABMR患者1年和3年移植物存活率显著降低,移植物失败风险比为10.33。

要点

  • 高致敏肾移植受者移植后2周内方案活检可早期发现veABMR。
  • veABMR患者移植物失败风险显著增高(HR 10.33)。
  • 供者特异性抗体II类及eplet错配(尤其DQA1)与veABMR相关。

核心结论

  • 在高免疫风险肾移植受者中,早期方案活检有助于及时发现veABMR。
  • veABMR患者尽管接受早期抗排斥治疗,仍面临显著的移植物丢失风险。

研究设计与样本

  • 研究评估了2015年至2022年间155例移植前cPRA I+II类>90%的高致敏肾移植受者。
  • 纳入移植后2周内接受方案活检的122例患者,中位随访期间分析ABMR发生及移植物存活。

主要发现

  • 122例中13例(10.6%)在移植后2周内诊断为veABMR,占随访期间所有ABMR病例(25例)的52%。
  • veABMR患者1年和3年移植物存活率显著低于早期方案活检无排斥患者(P < .001)。
  • veABMR患者移植物失败的风险比为10.33(95% CI 3.23-33.06,P < .001)。
  • 移植当天存在供者特异性抗体II类及更高比例的eplet错配(尤其EpMM DQA1)与veABMR发生相关。

临床怎么用

  • 对于高致敏肾移植受者,可考虑在移植后2周内进行方案活检以早期发现veABMR。
  • 移植前评估供者特异性抗体II类及eplet错配(尤其DQA1)有助于识别veABMR高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal transplant recipients with donor-specific anti-HLA antibodies are at an increased risk of antibody-mediated rejection (ABMR). Early protocolized renal biopsies may serve as a strategy to improve diagnosis in this patient population. METHODS: We evaluated 155 highly sensitized renal transplant recipients with cPRA class I + II >90% pre-transplant from 2015 to 2022. Patients with protocol biopsies within the first 2 weeks post-transplant were included. RESULTS: A total of 122 patients were included in the study. Of these, 13 (10.6%) were diagnosed with very early antibody-mediated rejection (veABMR) within the first 2 weeks post-transplant. This corresponds to 52% (13/25 patients) of all ABMR cases reported during the follow-up of this population. The graft survival rates at 1 and 3 years were significantly lower in patients with veABMR (P < .001) compared with patients without rejection in the early protocol biopsy. In terms of severity, the veABMR cohort exhibited a hazard ratio (HR) of 10.33 (95% confidence interval 3.23-33.06, P < .001) for graft failure. The presence of donor-specific antibodies class II on the day of transplantation and a higher percentage of eplet mismatch (EpMM), particularly EpMM DQA1, correlated with the development of veABMR. CONCLUSION: Early protocol biopsies play a pivotal role in the early detection of veABMR in high-risk immunological patients. Patients with veABMR face significant risks of graft loss, despite early treatment of rejection.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Arana C, Hermida E, Rovira J, et al. Antibody-mediated rejection diagnosed in early protocol biopsies in high immunological risk kidney transplant recipients. Nephrol Dial Transplant. 2025. PMID: 39257033. doi:10.1093/ndt/gfae186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。